Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 1, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Chronic Myeloid LeukemiaPayerPolicy · CAPBLUE-MP-9.039 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaPayerPolicy · CAPBLUE-MP-9.038 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for CNS Embryonal Tumors and EpendymomaPayerPolicy · CAPBLUE-MP-9.050 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Autoimmune DiseasesPayerPolicy · CAPBLUE-MP-9.053 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaPayerPolicy · CAPBLUE-MP-9.040 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Acute Lymphoblastic LeukemiaPayerPolicy · CAPBLUE-MP-9.041 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Handheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins During Breast Conserving SurgeryPayerPolicy · CAPBLUE-MP-5.055 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Germline Genetic Testing for Pancreatic Cancer Susceptibility GenesPayerPolicy · CAPBLUE-MP-2.392 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Germline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1,CTNNA1)PayerPolicy · CAPBLUE-MP-2.384 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)PayerPolicy · CAPBLUE-MP-2.211 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Prostate Cancer (Brca1/2, Homologous Recombination Repair Gene Alterations, Ntrk Gene Fusion)PayerPolicy · CAPBLUE-MP-2.394 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Ovarian Cancer (Brca1, Brca2, Homologous Recombination Deficiency, Ntrk)PayerPolicy · CAPBLUE-MP-2.395 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Breast Cancer (Brca1, Brca2, Pik3ca, Ki-67, Ret, Braf, Esr1, Ntrk)PayerPolicy · CAPBLUE-MP-2.393 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genotyping for 9p21 Single Nucleotide Polymorphism to Predict Risk of Cardiovascular Disease and AneurysmPayerPolicy · CAPBLUE-MP-2.311 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genotype-Guided Warfarin DosingPayerPolicy · CAPBLUE-MP-2.306 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genotype-Guided Tamoxifen TreatmentPayerPolicy · CAPBLUE-MP-2.307 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing of CADASIL SyndromePayerPolicy · CAPBLUE-MP-2.247 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for the Diagnosis of Inherited Peripheral NeuropathiesPayerPolicy · CAPBLUE-MP-2.355 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Predisposition to Inherited Hypertrophic CardiomyopathyPayerPolicy · CAPBLUE-MP-2.248 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Pathogenic FMR1 Variants (Including Fragile X Syndrome)PayerPolicy · CAPBLUE-MP-2.276 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for PTEN Hamartoma Tumor SyndromePayerPolicy · CAPBLUE-MP-2.255 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for NeurofibromatosisPayerPolicy · CAPBLUE-MP-2.358 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Mitochondrial DisordersPayerPolicy · CAPBLUE-MP-2.273 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related DisordersPayerPolicy · CAPBLUE-MP-2.331 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Macular DegenerationPayerPolicy · CAPBLUE-MP-2.260 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Lynch Syndrome and Inherited Colon Cancer SyndromesPayerPolicy · CAPBLUE-MP-5.013 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin TreatmentPayerPolicy · CAPBLUE-MP-2.310 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Limb Girdle Muscular DystrophiesPayerPolicy · CAPBLUE-MP-2.332 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Li-Fraumeni SyndromePayerPolicy · CAPBLUE-MP-2.274 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Inherited ThrombophiliaPayerPolicy · CAPBLUE-MP-2.253 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Idiopathic Dilated CardiomyopathyPayerPolicy · CAPBLUE-MP-2.328 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Heterozygous Familial HypercholesterolemiaPayerPolicy · CAPBLUE-MP-2.363 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Hereditary PancreatitisPayerPolicy · CAPBLUE-MP-2.318 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Hereditary HemochromatosisPayerPolicy · CAPBLUE-MP-2.312 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Hereditary Hearing LossPayerPolicy · CAPBLUE-MP-2.319 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Helicobacter Pylori TreatmentPayerPolicy · CAPBLUE-MP-2.308 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Fanconi AnemiaPayerPolicy · CAPBLUE-MP-2.362 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Familial Cutaneous Malignant MelanomaPayerPolicy · CAPBLUE-MP-2.246 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Facioscpulohumeral Muscular DystrophyPayerPolicy · CAPBLUE-MP-2.321 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for FLT3, NPM1 and CEBPA Variants in Cytogenetically Normal Acute Myeloid LeukemiaPayerPolicy · CAPBLUE-MP-2.357 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for EpilepsyPayerPolicy · CAPBLUE-MP-2.262 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Duchenne and Becker Muscular DystrophyPayerPolicy · CAPBLUE-MP-2.257 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Diagnosis and Management of Mental Health ConditionsPayerPolicy · CAPBLUE-MP-2.264 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for DD, ID, Autism Spectrum Disorder and CAPayerPolicy · CAPBLUE-MP-2.242 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Cardiac Ion ChannelopathiesPayerPolicy · CAPBLUE-MP-2.233 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for CHARGE SyndromePayerPolicy · CAPBLUE-MP-2.322 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Alzheimer Disease (Formerly Diagnostic Testing and Risk Assessment for Alzheimer Disease)PayerPolicy · CAPBLUE-MP-2.050 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Alpha-1 Antitrypsin DeficiencyPayerPolicy · CAPBLUE-MP-2.251 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Testing for Alpha ThalassemiaPayerPolicy · CAPBLUE-MP-2.320 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Genetic Cancer Susceptibility Panels Using Next Generational SequencingPayerPolicy · CAPBLUE-MP-2.325 | Metadata changed |
|---|